|1.||Schmidt, Ann Marie: 41 articles (12/2015 - 05/2002)|
|2.||Bierhaus, Angelika: 20 articles (08/2014 - 06/2004)|
|3.||Yamamoto, Hiroshi: 18 articles (12/2014 - 02/2005)|
|4.||Yamamoto, Yasuhiko: 15 articles (12/2014 - 03/2005)|
|5.||Yan, Shi Fang: 14 articles (02/2012 - 05/2002)|
|6.||Yamagishi, Sho-ichi: 13 articles (04/2015 - 02/2004)|
|7.||Nawroth, Peter P: 13 articles (07/2013 - 04/2003)|
|8.||Ramasamy, Ravichandran: 12 articles (12/2015 - 11/2003)|
|9.||Oury, Tim D: 10 articles (09/2015 - 11/2004)|
|10.||Schmidt, A M: 9 articles (08/2015 - 04/2000)|
10/15/2011 - "In the current study, we investigated the effect of oxidative stress on activation of the Receptor for Advanced Glycation End-products (RAGE) and subsequent protection against H(2)O(2)-induced pancreatic tumor cell damage. "
12/01/2015 - "We hypothesized that the pathological receptor for advanced glycation end products (RAGE) is involved in the PGZ anti-tumor process. "
03/01/2015 - "Polymorphisms in the receptor for advanced glycation end products (RAGE) gene may influence the risk of cancer, but the results are inconsistent. "
01/01/2015 - "The receptor for advanced glycation endproducts (RAGE) is an oncogenic multidisciplinary trans-membranous receptor, which is overexpressed in multiple human cancers. "
01/01/2015 - "Here, we present the receptor for advanced glycation end products (RAGE) and S100A8/A9 as important factors driving normal and tumor keratinocyte proliferation. "
|2.||Alzheimer Disease (Alzheimer's Disease)
04/29/2014 - "To examine safety, tolerability, and efficacy of PF-04494700, an inhibitor of the receptor for advanced glycation end products (RAGE), in mild to moderate Alzheimer disease (AD). "
10/13/2006 - "We noted in an earlier study that individuals with Alzheimer's disease exhibit enhanced expression of the receptor for advanced glycation end-products (RAGE) on the surface of their leukocytes. "
05/22/2014 - "In an effort to develop novel inhibitors of receptor for advanced glycation end products (RAGE) for the treatment of Alzheimer's disease, a series of pyrazole-5-carboxamides were designed, synthesized and biologically evaluated. "
01/01/2014 - "The receptor for advanced glycation end products (RAGE) has been reported to have a pivotal role in the pathogenesis of Alzheimer's disease (AD). "
07/01/2011 - "PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease."
03/01/2015 - "Receptor for advanced glycation end products (RAGE) blockade by a soluble form of RAGE (sRAGE) appears to be protective against hepatocellular death and necrosis after I/R injury. "
11/01/2012 - "In turn, ablation of S100B resulted in neuroprotection, reduced microgliosis and reduced expression of both the receptor for advanced glycation endproducts and tumour necrosis factor-α. "
01/01/2015 - "Receptor for advanced glycation end products (RAGE) plays a central role in the regulation of tissue homeostasis, regeneration and resolution of inflammation, but under pathological conditions RAGE-mediated pathways may induce diminished apoptosis, but enhanced autophagy and cell necrosis. "
02/01/2013 - "HMGB1 induced tumour necrosis factor-α secretion via Toll-like receptor (TLR)4 in U937 monocytes; however, HMGB1 decreased the number of U937 cells, resulting in restriction of immune activation via receptor for advanced glycation endproducts (RAGE). "
09/01/2009 - "Cell stress or necrosis lead the release of HMGB1 and S100 proteins in the extracellular compartment where they act as damage-associated molecular pattern molecules (or alarmins) by engaging the receptor for advanced glycation end-products (RAGE). "
06/01/2014 - "More importantly, treatment of animals with soluble form of receptor for advanced glycation endproducts, blockade of advanced glycation endproducts signaling, alleviated severe burn-induced insulin resistance. "
06/01/2014 - "Early glycemic control with insulin or inhibition of advanced glycation endproducts with soluble form of receptor for advanced glycation endproducts ameliorates postburn insulin resistance."
06/01/2014 - "We hypothesized that the receptor for advanced glycation end products (RAGE) and the ligand N(ε)-(carboxymethyl)lysine (CML) are increased in adipose tissue and, moreover, that activation of the CML-RAGE axis plays an important role in obesity-associated inflammation and insulin resistance. "
01/01/2012 - "The progress in this field lends strong support to several mechanisms that could affect these two diseases, including insulin resistance and signaling, vascular injuries, inflammation, and the receptor for advanced glycation endproducts and their ligands. "
02/01/2006 - "Treatment of db/db mice with soluble receptor for advanced glycation end-products (RAGE) prevented recruitment of macrophages to the glomeruli and reduced albuminuria, suggesting that binding of ligands and RAGE may be involved in MCP-1 expression. "
11/01/2013 - "Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) - receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes."
11/01/2013 - "To examine the effects of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the advanced glycation end product (AGE)-receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes patients. "
|4.||HMGB1 Protein (HMG1)
|5.||Biological Markers (Surrogate Marker)
|7.||Advanced Glycosylation End Products
|8.||Toll-Like Receptors (Toll-Like Receptor)
|4.||Drug Therapy (Chemotherapy)
|5.||Angioplasty (Angioplasty, Transluminal)